TwoStep Therapeutics secures $62.5m to advance TS-104

TwoStep Therapeutics has raised $62.5m in Series A financing to support its lead peptide-drug conjugate, TS-104, to treat solid tumours. TwoStep will begin a Phase I study of TS-104, with patient enrolment expected to commence later this year. TwoStep’s approach uses a PIP that is designed to bind five tumour-associated integrins present in various solid tumours. Credit: angellodeco / Shutterstock.com. TwoStep Therapeutics has raised $62.5m in an oversubscribed Series A financing round to support its lead peptide-drug conjugate, TS-104, for the treatment of solid tumours. Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures…

Source: Pharmaceutical Technology